awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q41145898-A44C0C2C-50C5-4332-B00F-E415717EA382
Q41145898-A44C0C2C-50C5-4332-B00F-E415717EA382
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41145898-A44C0C2C-50C5-4332-B00F-E415717EA382
Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.
P2860
Q41145898-A44C0C2C-50C5-4332-B00F-E415717EA382
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41145898-A44C0C2C-50C5-4332-B00F-E415717EA382
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2a5cd4f3a041607d793046592227fd3d5bfba7b3
P2860
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.